Dr. Hill Discusses Combinations in MCL

Brian T. Hill, MD, PhD
Published: Monday, Feb 26, 2018



Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma (MCL).

There is a lot of interest in combining Bruton's tyrosine kinase inhibitors with other agents, says Hill, including ibrutinib (Imbruvica) plus venetoclax (Venclexta) and ibrutinib plus ixazomib (Ninlaro). Ixazomib is an oral proteasome inhibitor that has known activity in patients with MCL.

The ongoing phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax in patients with relapsed/refractory MCL. Individually, both agents have achieved response rates of 67% to 75% in this patient population.

Ibrutinib is also being combined with monoclonal antibodies, which Hill says could be an interesting treatment strategy for patients with MCL.
SELECTED
LANGUAGE


Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma (MCL).

There is a lot of interest in combining Bruton's tyrosine kinase inhibitors with other agents, says Hill, including ibrutinib (Imbruvica) plus venetoclax (Venclexta) and ibrutinib plus ixazomib (Ninlaro). Ixazomib is an oral proteasome inhibitor that has known activity in patients with MCL.

The ongoing phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax in patients with relapsed/refractory MCL. Individually, both agents have achieved response rates of 67% to 75% in this patient population.

Ibrutinib is also being combined with monoclonal antibodies, which Hill says could be an interesting treatment strategy for patients with MCL.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x